150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?

Introduction

Sodium-glucose co-transporter (SGLT2) inhibition has been shown to reduce the risk of cardiovascular death or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF) with or without type 2 diabetes mellitus (T2DM). Since publication of the DAPA-HF¹ and EMPEROR-HF² trials and UK NICE approval,³ SGLT2 inhibitor prescription has been increasing for patients with...